While there were no statistically significant differences in comorbid conditions between the groups, there was a slight trend towards a higher prevalence of hypertension, coronary artery disease, and CKD among non-users of SGLT2 inhibitors.
← all excerpts
Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study.
1
—
—